Get started
Syndax Pharmaceuticals, Inc.Syndax Pharmaceuticals, Inc.Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

SNDX chart


Full chart

SNDX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.18 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.73 USD
Net income (FY)
‪−318.76 M‬ USD
Revenue (FY)
‪23.68 M‬ USD
Shares float
‪84.18 M‬
Beta (1Y)
1.70

Employees


Employees (FY)
270
Change (1Y)
+86 +46.74%
Revenue / Employee (1Y)
‪87.70 K‬ USD
Net income / Employee (1Y)
‪−1.18 M‬ USD

About Syndax Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Michael A. Metzger
Website
syndax.com
Headquarters
New York
Founded
2005
FIGI
BBG000R33JY1
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SNDX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as SNDX.

Frequently Asked Questions


The current price of SNDX is 13.67 USD — it has increased by 2.09% in the past 24 hours. Watch Syndax Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Syndax Pharmaceuticals, Inc. stocks are traded under the ticker SNDX.
SNDX stock has risen by 13.22% compared to the previous week, the month change is a 0.66% rise, over the last year Syndax Pharmaceuticals, Inc. has showed a −34.12% decrease.
We've gathered analysts' opinions on Syndax Pharmaceuticals, Inc. future price: according to them, SNDX price has a max estimate of 51.00 USD and a min estimate of 16.00 USD. Watch SNDX chart and read a more detailed Syndax Pharmaceuticals, Inc. stock forecast: see what analysts think of Syndax Pharmaceuticals, Inc. and suggest that you do with its stocks.
SNDX reached its all-time high on Feb 2, 2023 with the price of 29.86 USD, and its all-time low was 3.39 USD and was reached on Dec 26, 2018. View more price dynamics on SNDX chart.
See other stocks reaching their highest and lowest prices.
SNDX stock is 4.79% volatile and has beta coefficient of 1.70. Track Syndax Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Syndax Pharmaceuticals, Inc. there?
Today Syndax Pharmaceuticals, Inc. has the market capitalization of ‪1.18 B‬, it has increased by 3.87% over the last week.
Yes, you can track Syndax Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Syndax Pharmaceuticals, Inc. is going to release the next earnings report on May 5, 2025. Keep track of upcoming events with our Earnings Calendar.
SNDX earnings for the last quarter are −1.10 USD per share, whereas the estimation was −0.84 USD resulting in a −31.17% surprise. The estimated earnings for the next quarter are −1.27 USD per share. See more details about Syndax Pharmaceuticals, Inc. earnings.
Syndax Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪7.68 M‬ USD, despite the estimated figure of ‪35.10 M‬ USD. In the next quarter, revenue is expected to reach ‪14.59 M‬ USD.
SNDX net income for the last quarter is ‪−94.17 M‬ USD, while the quarter before that showed ‪−84.13 M‬ USD of net income which accounts for −11.94% change. Track more Syndax Pharmaceuticals, Inc. financial stats to get the full picture.
No, SNDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 30, 2025, the company has 270 employees. See our rating of the largest employees — is Syndax Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Syndax Pharmaceuticals, Inc. EBITDA is ‪−339.66 M‬ USD, and current EBITDA margin is ‪−1.43 K‬%. See more stats in Syndax Pharmaceuticals, Inc. financial statements.
Like other stocks, SNDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Syndax Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Syndax Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Syndax Pharmaceuticals, Inc. stock shows the sell signal. See more of Syndax Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.